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How cells sense and respond to environmental cues remains a central question of biological research.
Recent evidence suggests that DNA transcription is regulated by chromatin organization. However, the
mechanism for relaying the cytoplasmic signaling to chromatin remodeling remains incompletely under-
stood. Although much emphasis has been put on delineating transcriptional output of growth factor/
hormonal signaling pathways, accumulated evidence from yeast and mammalian systems suggest that
metabolic signals also play critical roles in determining chromatin structure. Here we summarize recent prog-
ress in understanding the molecular connection between metabolism and epigenetic modifications of chro-
matin implicated in a variety of diseases including cancer.Introduction
Cells, whether as unicellular organisms or within a multicellular
organism, need to make various ‘‘decisions’’ throughout their
lifetime. Every choice—quiescence, proliferation, differentiation
or migration—is made in the face of the constantly changing
environment. Metazoan cells have developed elegant mecha-
nisms to sense and integrate extracellular information into an
intrinsic signaling system that regulates transcription so that
variations in the form of growth factors, hormones, and stromal
interactions can be delivered and responded to in a timely and
accurate manner. Studying these mechanisms remains a major
focus of biological research and has profound implications in
understanding human physiology and diseases.
One of the most exciting advances over the past 15 years
is the field of epigenetics (meaning ‘‘above’’ genetics). We
now know that in addition to primary DNA sequence informa-
tion, much of the information regarding when and where to
initiate transcription is stored in covalent modifications of DNA
and its associated proteins. The patterns of various modifica-
tions along the chromatin, such as DNA cytosine methylation
and hydroxymethylation, and acetylation, methylation, phos-
phorylation, ubiquitination, and SUMOylation of the lysine (K)
and/or arginine (R) residues of histones are thought to determine
the genome accessibility to transcriptional machinery. For ex-
ample, acetylation of histone lysine residues and methylation
of H3K4, H3K36, and H3K79 are associated with active tran-
scription while methylation of DNA, H3K9, H3K27, and H4K20
generally indicates silenced chromatin. In many instances, such
information is heritable. The complexity and dynamics of epige-
netic modifications are considered to provide a link between the
extracellular environment and nuclear transcription. It is increas-
ingly apparent that many growth factor/hormone-responsive
signaling pathways such as Notch and TGFb, often in conjunc-
tion with downstream transcription factors, can remodel the
epigenome through expressing, recruiting or editing enzymes
that modify chromatin (Mohammad and Baylin, 2010). One
good example is the Notch effector RBP-J: depending on the
presence of activated Notch, RBP-J recruits distinct histone-
modifying enzymes to activate or repress target gene expres-
sion (Liefke et al., 2010).A less studied but recently emerged concept is that informa-
tion about a cell’s metabolic state is also integrated into the
regulation of epigenetics and transcription (Figure 1). It is now
appreciated that cells constantly adjust their metabolic state in
response to extracellular signaling and/or nutrient availability
(Vander Heiden et al., 2009). As a classical example, while quies-
cent cells fully oxidize glucose to carbon dioxide in themitochon-
drial electron transport chain; proliferative cells and tumor cells
consume much larger quantities of glucose, secreting excess
carbon as lactate even when oxygen is abundant, a process
termed ‘‘aerobic glycolysis.’’ Connections between metabolism
and transcription are not unexpected. In unicellular organisms
like yeast the major determinant of cell fate is nutrient levels.
Even in metazoans where most cellular signaling events are
dictated by growth factors, cytokines or hormones, metabolism
still plays a significant role in transcription. This also has a poten-
tially unifying logic, as most chromatin-modifying enzymes
require substrates or cofactors that are intermediates of cell
metabolism. It is not difficult to imagine that fluctuation ofmetab-
olite levels could modulate the activities of chromatin-modifying
enzymes and therefore influence chromatin dynamics. As many
complex diseases such as cancer and type II diabetes display
abnormalities of cellular metabolism and epigenome, under-
standing the molecular connections between these processes
may have therapeutic implications.
In this perspective, we will review findings from studies that
examine metabolic inputs into epigenetics and transcription
in both yeast and metazoan organisms. We discuss possible
mechanisms of howmetabolism can influence chromatin states,
and review recent efforts linking metabolic perturbation to the
dysregulation of cellular differentiation.
Metabolites Drive Oscillatory Gene Expression during
Yeast Metabolic Cycle
Most laboratory strains of budding yeast Saccharomyces cerevi-
siae are cultured in media with abundant nutrient supply. As
unicellular organisms, yeast under such conditions uptake extra-
cellular nutrients avidly and exploit nutrient capture to fuel cell
growth and proliferation at a logarithmic rate. However, under
conditions where one or more nutrients are limiting, yeast tendCell Metabolism 16, July 3, 2012 ª2012 Elsevier Inc. 9
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Figure 1. Signaling and Metabolic Inputs into
Epigenetics
Growth factors, hormones, and cytokines activate the
classical signaling pathways and downstream transcrip-
tional factors which will recruit chromatin-modifying
enzymes to local chromatin. On the other hand, nutrient
levels and cell metabolism will affect levels of the
metabolites which are required substrates of chromatin-
modifying enzymes that use these metabolites to
modify both histones and DNA. Variations in these two
inputs will determine the epigenome remodeling and
transcription.
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characterized by robust changes in oxygen consumption
(Chance et al., 1964). These metabolic oscillations can vary
from minutes to hours depending on yeast strains and experi-
mental conditions and are independent of cell division cycle
(Slavov et al., 2011). Remarkably, when genome-wide gene
expression in yeast under such culture system was analyzed,
nearly 60% of the genes were expressed in a similarly cyclic
fashion (Klevecz et al., 2004; Tu et al., 2005).
These data suggest that metabolite levels might be contrib-
uting to the temporal control of gene expression. This is sup-
ported by the observations that transient administration of
metabolites, particularly the glycolytic intermediates, could
initiate phase advancement in the oscillatory cycle (Cai et al.,
2011; Tu andMcKnight, 2009). Levels of acetyl-CoA, the product
of glycolytic metabolism and a donor to acetylation reactions,
were found to oscillate dynamically and peak during the oscilla-
tory growth phase (Cai et al., 2011; Tu et al., 2007). Genome-
wide analysis of H3K9 acetylation showed that its enrichment
at genes expressed during growth phase correlated with
acetyl-CoA levels and was dependent on the generation of
acetyl-CoA (Cai et al., 2011). Therefore it appears that levels of
acetyl-CoA can be instructive for cells to engage growth at least
in part through modulating histone acetylation and transcription
of growth genes. Such a mechanism may well operate at other
times. For example, the exit of yeast from quiescence has
been reported to require glucose catabolism but not cell cycle
signaling (Laporte et al., 2011). Whether metabolites in addition
to acetyl-CoA contribute to these regulatory events remains to
be investigated.
Potential Link between Metabolism and Transcriptional
regulation by the Circadian System
Unlike yeast, metazoan cells lack the autonomous ability to up-
take and metabolize nutrients. Instead cellular nutrient uptake
is under the control of a mixture of growth factor, paracrine
and hormonal signaling. These factors control the positions
that differentiated cells can survive in the body and dictate the
share of the body’s resources a cell can utilize in maintaining
itself. In addition, the metabolism of individual cells must be en-
trained to the activities of the organism as a whole. One way this
is accomplished is through the circadian system, which has10 Cell Metabolism 16, July 3, 2012 ª2012 Elsevier Inc.evolved to allow organisms to adapt to the
24 hr day-night cycles on Earth. The circadian
system regulates many aspects of animal
behavior and physiology. It consists of a central
clock, which is located in the hypothalamicsuprachiasmatic nucleus and responsive to light; and peripheral
clocks, which are present in many non-light sensitive organs.
The molecular mechanism for the circadian system includes a
number of transcriptional and posttranslational feedback loops.
In brief, CLOCK and BMAL1, central transcriptional factors of
the circadian system, regulate the expression of cryptochrome
(CRY1 and CRY2) and period (PER1, PER2, and PER3). CRY
and PER proteins in turn negatively regulate CLOCK-BMAL1
complex. Before a new cycle begins, CRY and PER proteins
are degraded which de-represses the activities of CLOCK-
BMAL1 complex (Figure 2).
While light is the regulator of the central clock, there is compel-
ling evidence linking peripheral clocks to metabolism. Bmal1/
and Clockmut mice exhibit various abnormalities of glucose and
lipid homeostasis (Oishi et al., 2006; Rudic et al., 2004; Turek
et al., 2005). On the other hand, temporally restricted feeding
has been shown to be a powerful entraining stimulus in several
organisms (Damiola et al., 2000; Xu et al., 2011a). Moreover,
high-fat diet could alter animals’ daily rhythm and the cycling
of circadian clock genes (Kohsaka et al., 2007). In cell culture,
glucose was demonstrated to modulate the circadian rhythm
(Hirota et al., 2002). In humans, it has been shown that circadian
misalignment could cause aberrant glucose response indicative
of a prediabetic state (Scheer et al., 2009).
How peripheral clocks sense the metabolic state remains
incompletely understood. Several reports suggested NAD+/
NADH as a central player between metabolism and circadian
system (Figure 2). Two NAD+-dependent proteins, SIRT1 deace-
tylase andPARP1ADP-ribosyltransferase,were shown to bind to
CLOCK-BMAL1 complex and affect its DNA binding activity and
target gene expression (Asher et al., 2008, 2010; Nakahata et al.,
2008). Part of SIRT1’s effect oncircadiangene transcriptioncould
be attributed to its deacetylase activity toward histones at the
promoters of circadian genes (Nakahata et al., 2008). The inhibi-
tion of nicotinamide phosphoribosyltransferase (NAMPT), a key
enzyme in the NAD+ salvage pathway, promotes the oscillation
of CLOCK-BMAL1 target genes, demonstrating a critical role of
NAD+ in the functioning of circadian clock (Nakahata et al.,
2009; Ramsey et al., 2009). Interestingly, NAD+ levels also oscil-
late in a circadianclock-dependent fashionandNAMPT is adirect
transcriptional target of the CLOCK-BMAL1 complex, thus
completing a metabolic feedback loop of the circadian system.
Figure 2. Metabolic Feedback Loop of the
Circadian Clock
As master regulators of the circadian clock, CLOCK
and BMAL1 control the expression of CRY and PER. CRY
and PER proteins in turn regulate CLOCK-BMAL1
complex activity. Recently SIRT1 was found to bind to
CLOCK-BMAL1 complex and negatively regulate its
target gene transcription by deacetylating histones. SIRT1
activity depends on NAD+. Increased glucose metabolism
converts nuclear/cytoplasmic NAD+ to NADH and
suppresses SIRT1. Another NAD+-dependent enzyme is
PARP1 which catalyzes the polymerization of ADP-ribose
units on proteins and generates nicotinamide. The gen-
eration of additional cytosolic NAD+ requires the rate-
limiting enzyme NAMPT. The cyclic expression of NAMPT
is under the control of CLOCK-BMAL1, therefore con-
tributing to a metabolic feedback loop. The energy-
responsive kinase AMPK can also affect molecular clock
machinery by phosphorylating CRY1 and facilitating
its degradation. AMPK also phosphorylates histones,
though its implication on the circadian system remains
unclear.
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be sensed by signaling proteins which directly or indirectly
modulate the molecular clock machinery. For example, the
energy-responsive AMP-activated protein kinase (AMPK) phos-
phorylates and facilitates the degradation of CRY1 (Lamia et al.,
2009). In mice and cells where AMPK pathway is deficient, the
peripheral circadian clock is disrupted (Lamia et al., 2009; Um
et al., 2011). Other nutrient sensors such as mTOR and AKT
were also shown to linkmetabolic signals to the circadian system
(Zheng and Sehgal, 2010). Both AMPK and AKT contribute to the
regulation of histone phosphorylation (see below), suggesting
that chromatin remodeling represents part of the underlying
mechanism.
Metabolic Regulation of Epigenetics
Over the past 15 years, various enzymes responsible for adding
or removing epigenetic modifications have been identified and
functionally characterized. These enzymes include but are not
limited to DNA methyltransferases (DNMTs), DNA hydroxylases
(DNHDs), histone acetyltransferases (HATs), histone deacety-
lases (HDACs), histone methyltransferases (HMTs), and histone
demethylases (HDMs). As discussed above, the activities of
many chromatin-modifying enzymes are regulated in part by
the concentrations of their required metabolic substrates or
cofactors. Such substrates or cofactors are capable of diffusing
through nuclear pores, therefore providing a way for the cell to
deliver metabolic information to nuclear transcription (Figure 3).
Histone Acetylation
Histone acetylation is catalyzed by HATs. Mammalian HATs are
divided into five families which share a similar enzymatic reac-
tion: HATs transfer the acetyl group of the acetyl-CoA to the
lysine residues of histones and produce CoA as an end product
(Racey and Byvoet, 1971). As demonstrated in yeast, elevated
levels of acetyl-CoA can be sufficient to instruct cells to enter
growth by promoting histone acetylation and expression of
growth-related genes (Cai et al., 2011), suggesting that theavailability of acetyl-CoA is a major metabolic input into histone
acetylation. Indeed, it was shown that depending on the meta-
bolic state, intracellular acetyl-CoA concentration shows a
10-fold variation (Cai et al., 2011; Takamura and Nomura,
1988). Since the Km of most HATs is within the range (Tanner
et al., 1999), the activities of HATs are likely sensitive to the
fluctuation of intracellular acetyl-CoA levels.
In mammalian cells, most cytosolic acetyl-CoA comes from
citrate exported from mitochondria by a reaction catalyzed by
ATP-citrate lyase (ACL). Enhanced glycolysis drives citrate
synthesis and therefore the generation of cytosolic acetyl-CoA.
Tracing experiments using 13C-labeled glucose in Myc-stimu-
lated cells showed that about half of the acetyl groups on
H4K16 came from glucose-derived acetyl-CoA (Morrish et al.,
2010). Citrate produced from metabolism of glutamine in the
TCA cycle can also contribute to the production of cytosolic
acetyl-CoA (Metallo et al., 2012; Mullen et al., 2012; Wise
et al., 2011). In cells where ACL was knocked down, there was
a profound defect in histone acetylation and expression of genes
regulating glucose metabolism (Wellen et al., 2009). In yeast,
abrogation of cytosolic acetyl-CoA generating enzymes leads
to global histone hypoacetylation (Takahashi et al., 2006).
Histone Deacetylation
Enzymes that catalyze the removal of histone acetylation can
be in principle divided into two groups based on structural and
mechanistic similarities: classical HDACs and NAD+-dependent
sirtuin family deacetylases. The deacetylation reaction is ener-
getically favorable. Therefore sirtuins are intriguing as they
catalyze the reaction in a seemingly wasteful way: one NAD+
molecule is hydrolyzed to yield nicotinamide and O-acetyl-
ADP-ribose. The substrates of sirtuins are diverse and among
seven members of the mammalian sirtuin family, SIRT1 and
SIRT6 have been shown to localize to the nucleus and exhibit
HDAC activities (Imai et al., 2000; Kawahara et al., 2009).
The link between sirtuins and metabolic sensing was sup-
ported by the findings that Sir2, first sirtuin gene identified inCell Metabolism 16, July 3, 2012 ª2012 Elsevier Inc. 11
Figure 3. Crosstalk between Metabolism
and Epigenetics
As glucose enters the glycolytic pathway, a minor
portion is branched to hexosamine biosynthetic
pathway to produce GlcNAc which can be used
as substrate for histone GlcNAcylation by OGT.
Flux through glycolysis determines the NAD+/
NADH ratio which is important for the activities
of sirtuin histone deacetylases. Several TCA cycle
intermediates can be exported out of mitochon-
dria including citrate and aKG. Cytosolic citrate is
converted to acetyl-CoA which is used as a donor
for HAT-mediated histone acetylation. aKG is
used as cofactor for histone and DNA demethy-
lation reactions by JHDM and TET, respectively.
The substrate for HMT and DNMT is SAM, which
is synthesized from essential amino acid methio-
nine. Finally, a low ATP/AMP ratio can activate
AMPK, a kinase that phosphorylates histones.
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life span. It is known that glucose limitation in yeast increases life
span. When Sir2 was mutated in some yeast strains, the life
extension effect of CR was lost (Lin et al., 2000). Deacetylation
of H4K16 appears to be essential for the antiaging effect
of Sir2 (Dang et al., 2009b). One potential mechanism is that
CR in yeast increases respiration and therefore generates a
more oxidized environment and a high NAD+/NADH ratio (Lin
et al., 2002). Alternatively, CR was shown to decrease nicotin-
amide levels and increase NAD+ salvage pathway flux (Anderson
et al., 2003). Further flux analysis examining the cytosolic source
of NAD+ would be needed to better understand how CR
activates sirtuins (Locasale and Cantley, 2011). Moreover,
O-acetyl-ADP-ribosemight also serve as an important metabolic
signal, as it functions to assemble the SIR complex for chromatin
silencing in yeast (Liou et al., 2005).
DNA and Histone Methylation
DNMTs and HMTs add methyl groups to DNA or lysine/arginine
residues of histones, respectively. Although structurally diverse
and possessing high substrate specificities, DNMTs and HMTs
share a similar reaction mechanism: transferring a methyl group
from S-adenosyl methionine (SAM) to the substrate with the
formation of the by-product S-adenosyl homocysteine (SAH).
SAM is derived from the essential amino acidmethionine through
methionine adenosyltransferase (MAT). It is possible to alter
SAM levels through diets (Poirier et al., 2001). However, SAH is
a very potent inhibitor of DNMTs and HMTs and the key meta-
bolic determinant of methyltransferase reactions is the rate of
SAH clearance (Selhub andMiller, 1992). SAH can be hydrolyzed
to homocysteine. Homocysteine can be used to regenerate
methionine, a step catalyzed by methionine synthetase and
dependent on one-carbon metabolism. Alternately, homocys-
teine can enter the transulfuration pathway to generate cysteine,
the precursor for glutathione synthesis.
The complexity of SAM and SAH metabolism implies that
multiple metabolic inputs could affect the establishment of
DNA and histone methylation. Dietary intake of methyl donors
such as folate is closely linked to levels of DNA methylation,12 Cell Metabolism 16, July 3, 2012 ª2012 Elsevier Inc.which has been excellently reviewed elsewhere (Feil and Fraga,
2011; Kim, 2005). Acute depletion of glutathione led to drainage
of methionine pools and progressive DNA hypomethylation in
hamsters, potentially linking the redox status to epigenetic regu-
lation (Lertratanangkoon et al., 1997). It is expected that addi-
tional connections will unfold after further investigation of these
pathways.
DNA and Histone Demethylation
A covalent methyl group is chemically stable. Therefore DNA and
histone methylation were considered as relatively static epige-
netic marks. However during embryonic development there is
extensive remodeling of the cellular methylome, suggesting the
existence of enzymes that actively remove methylation marks.
Indeed in recent years, a variety of HDMs and DNHDs have
been identified. The first identified HDM is LSD1 (Shi et al.,
2004). The histone demethylation reaction catalyzed by LSD1
involves the reduction of cofactor flavin adenine dinucleotide
(FAD) to FADH2 and the release of formaldehyde as a by-
product. As recycling of FAD requires converting molecular
oxygen to hydrogen peroxide, cellular redox status might influ-
ence the availability of FAD and thus the activity of LSD1.
Subsequently a family of HDMs named Jumonji-C domain
containing HDM (JHDM) were identified and characterized
(Klose and Zhang, 2007). JHDM catalyzes a distinct demethyla-
tion reaction from LSD1: it utilizes a-ketoglutarate (aKG), oxygen
and Fe (II) as cofactors and releases succinate and formalde-
hyde as by-products. This mechanism was also adopted by
the newly identified TET family enzymes that hydroxylate the
5-methylcytosine of DNA. The only difference is that in this reac-
tion, the hydroxymethyl group is a stable product and further
TET-dependent modification is undertaken with low stoichiom-
etry (He et al., 2011; Ito et al., 2011). The function of 5-hydroxy-
methylcytosine is the topic of intensive investigation and thought
to serve as an intermediate for subsequent active (TET-depen-
dent) or passive (replication-dependent) demethylation (He
et al., 2011; Tahiliani et al., 2009).
Studies on the metabolic regulation of JHDM- and TET-medi-
ated demethylation are limited. However from the metabolic
Figure 4. Proposed Model for the Role of
2HG in Epigenetic Regulation and Cell
Differentiation
When progenitor cells differentiate, JHDM re-
moves repressive histone methylation marks
(H3K9me3 and H3K27me3) and activates the
expression of differentiation-related genes. In
addition, TET acts as a failsafe mechanism to
protect promoters from aberrant DNA methyla-
tion. 2HG produced by mutant IDH inhibits JHDM
and TET, which leads to histone and DNA hyper-
methylation and permanently ‘‘locks’’ differentia-
tion-related genes in a silent state. This results in
a differentiation arrest and expansion of progenitor
cells, thus facilitating tumor development.
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is interesting as it involves aKG and succinate, key metabolites
of the TCA cycle. aKG can be derived from either glucose
or glutamine and is involved in many anabolic pathways. It is
estimated that in proliferating cells the intracellular aKG concen-
trations vary from 0.5-3mMwhich iswell above the Km of JHDMs
(Chowdhury et al., 2011; Thirstrup et al., 2011). Nevertheless
upon stimuli such as glucagon or vasopressin, the levels of
aKG can rapidly drop as much as 60% (Staddon and McGivan,
1984). Moreover the transport of aKG between cytosol and
mitochondria is governed by aKG-malate carrier which is part
of the malate-aspartate shuttle that facilitates mitochondria-
cytosol transfer of NAD+ and NADH. It has been shown that
net flux of the malate-aspartate shuttle determines the rate of
aKG interchange between the two compartments (Hautecler
et al., 1994; Locasale and Cantley, 2011). Therefore there
is a possible metabolic link between HDACs and HDMs/DNHDs.
Although succinate was a weak inhibitor of JHDM in vitro (Rose
et al., 2008), pathological levels of succinate can affect histone
methylation (Cervera et al., 2009). These findings, though
circumstantial, suggest that the rate of demethylation could
be regulated at both levels of cofactor availability and feed-
back inhibition.
Histone Phosphorylation
Multiple serine and threonine residues of histones are subject to
phosphorylation by a wide array of kinases (Baek, 2011). Since
the intracellular ATP concentration is well above the Km of
most kinases, metabolism should not exert a direct effect on
histone phosphorylation. However, some kinases that are
responsive to metabolic changes can phosphorylate histones,
thus providing an indirect way for metabolic control of histone
phosphorylation. For example, in response to a low ATP/AMP
ratio indicative of metabolic stress, AMPK can translocate to
chromatin and phosphorylate histone H2B serine 36. The
H2BS36 phosphorylation facilitates the expression of AMPK-
dependent genes and is essential for metabolic adaptation and
cell survival under energetic stress (Bungard et al., 2010). Simi-
larly, the H3S10-specific kinase AKT is downstream of mTOR,
a well-characterized amino acid sensor in cells.
Histone GlcNAcylation
Recently a new modification of histone was reported. H2B S112
can be O-linked N-acetylglucosamine (GlcNAc)-modified by theenzyme O-GlcNAc transferase (OGT) (Fujiki et al., 2011). GlcNAc
comes from a minor branch of glycolytic metabolism called hex-
osamine biosynthetic pathway (HBP). About 5% of glucose
enters HBP and the end product GlcNAc is used as donor
for various protein glycosylation reactions. GlcNAc has been
reported to be a key signaling metabolite which can coordinate
glucose and glutamine metabolism in cells through glycosylation
of growth factor receptors (Wellen et al., 2010). Although the
transcriptional implication of histone GlcNAcylation remains to
be fully elucidated, it is likely that flux through HBP affects levels
of this novel epigenetic mark.
Lessons from IDH Mutation: Metabolic Reprogramming
and Epigenetics in Cancer
It was observed more than 50 years ago by the German
biochemist Otto Warburg that cancer cells utilize glucose in a
fundamentally different way than normal cells (Warburg, 1956).
Since then and with the recent outburst in cancer metabolism
research, metabolic reprogramming as a hallmark of cancer
has been increasingly appreciated (Vander Heiden et al.,
2009). However, one key question remains in the field: does
metabolism rewiring observed in cancer merely serve to fulfill
the proliferative demand of tumor cells or play a significant role
in driving cancer development? One strong argument in support
of the latter would be the identification of cancer-associated
mutations in metabolic enzymes. Recently the metabolic en-
zymes isocitrate dehydrogenase 1 (IDH1) and IDH2 were found
to be frequently mutated in low-grade gliomas (Yan et al.,
2009), adult de novo acute myeloid leukemias (AMLs) (Mardis
et al., 2009; Ward et al., 2010) and subsets of chondrosarcomas
and lymphomas (Amary et al., 2011; Cairns et al., 2012). IDH1
and IDH2 are NADP+ dependent enzymes that interconvert iso-
citrate and aKG in cytosol and mitochondria, respectively. The
mutations observed in IDH1 and IDH2 are heterozygous and
highly specific, suggesting a possible gain-of-function. Indeed,
metabolomic and biochemical analysis revealed that mutant
IDHs display a neomorphic activity of producing 2-hydroxygluta-
rate (2HG) from aKG (Dang et al., 2009a; Ward et al., 2010). In
IDH mutant patient samples, 2HG levels were found to be
elevated as high as 100-fold.
Since 2HG is a structural analog of aKG, it is plausible that
2HG modulates activities of enzymes dependent on aKG. In
humans there are more than 60 aKG-dependent enzymes
which affect diverse aspects of cell physiology (Loenarz andCell Metabolism 16, July 3, 2012 ª2012 Elsevier Inc. 13
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inhibit a number of aKG-dependent enzymes with varying
potencies, therefore the challenge is to identify key enzymes
that mediate 2HG’s oncogenic effect (Chowdhury et al., 2011;
Xu et al., 2011b). We speculated that if such enzyme exists,
one would expect to observe its mutations in the same malig-
nancy where IDH mutations were identified. Genetic profiling
of AML samples revealed that loss-of-function mutations of
TET2, amember of the TET family DNHDs, were frequently found
in AML and mutually exclusive with IDH mutations (Figueroa
et al., 2010). Expression ofmutant IDH in cells effectively blocked
TET2-induced increase in 5-hydroxymethylcytosine (Figueroa
et al., 2010). Consistently, cells stably expressing mutant IDH
and AML samples with IDHmutations showedDNA hypermethy-
lation. These findings suggest that in AML, IDH mutations and
TET2 mutations share a common tumorigenic pathway which
involves remodeling of the cellular epigenetic state.
Interestingly, IDH mutations are similarly associated with
DNA hypermethylation in gliomas where no mutations in the
TET family members have been identified so far (Noushmehr
et al., 2010). In vitro 2HG can competitively inhibit several
aKG-dependent JHDMs (Chowdhury et al., 2011; Xu et al.,
2011b). Given the close relationship between histone meth-
ylation and DNA methylation, it is tempting to speculate
that aberrant histone demethylation contributes to the DNA
hypermethylation phenotype in IDH mutant gliomas. Indeed,
glioma samples with IDH mutations displayed higher levels
of H3K9me3 and H3K27me3. In astrocyte cultures, stable ex-
pression of mutant IDH1 was sufficient to induce DNA hyperme-
thylation, an observation that was temporally preceded by
a progressive increase in H3K9me3 (Lu et al., 2012; Turcan
et al., 2012). Although mutations in chromatin-modifying
enzymes have not been identified in adult low-grade gliomas,
in pediatric gliomas genes encoding histone variants H3.3
(H3F3A) and H3.1 (HIST1H3B) were found to be somatically
mutated at specific residues including K27 which appeared to
be mutually exclusive with IDH mutations. Further functional
characterization of these specific histone mutations will be
needed to genetically link IDH mutations to histone methylation
in glioma (Schwartzentruber et al., 2012; Wu et al., 2012).
What is the consequence of epigenome aberration induced
by mutant IDH? It is well known that epigenetic remodeling
represents an important step in cell lineage specification and
a common feature of malignancies with IDH mutations is a block
to cell differentiation. When fibroblasts expressing mutant IDH
were induced to differentiate to adipocytes, there was a
profound defect in the expression of differentiation-related
genes (Lu et al., 2012). Interestingly, such failure was associ-
ated with increased repressive histone methylation including
H3K9me3 and H3K27me3 but not DNA methylation. These
data, together with the findings that (1) genes showing DNA
hypermethylation in cancer tend to be differentiation-related
and reversibly silenced by histone methylation in stem cells
(Ohm et al., 2007; Widschwendter et al., 2007), and (2) TET1
preferentially binds to the promoters of differentiation-related
genes and is thought to prevent accidental DNA methylation
(Williams et al., 2012; Wu and Zhang, 2011), suggest a working
model (Figure 4). During differentiation of progenitor cells,
JHDM inhibition by 2HG causes defective histone demethyla-14 Cell Metabolism 16, July 3, 2012 ª2012 Elsevier Inc.tion and blocks the accessibility of differentiation-related genes.
In addition, the inhibition of TET and JHDM by 2HG leads to
progressive DNA hypermethylation and permanently ‘‘locks’’
these genes in a silent state. The resulting differentiation arrest
may facilitate cancer development through accumulation of
undifferentiated cells capable of self-renewal. Future analysis
of DNA and histone methylation as well as the genome-wide
distribution of JHDM/TET binding will be required to test this
hypothesis.
The analyses of cancer-associated IDH mutations highlight
the dynamics and importance of the interaction between metab-
olism and epigenetics. As metabolic abnormalities in cancer
continue to be uncovered, it will be interesting to see if new
metabolites or metabolic perturbations that affect chromatin
structure are identified. For example, recently the key enzyme
in serine biosynthetic pathway, phosphoglycerate dehydroge-
nase (PHGDH), was found to be amplified in melanoma and
breast cancer (Locasale et al., 2011; Possemato et al., 2011).
As the flux to serine biosynthetic pathway regulates the one-
carbon metabolism which is critical for recycling of the methyl
donor methionine, PHGDH amplification could potentially modu-
late the cellular methylome and the epigenetic state.
Concluding Remarks
Research on metabolism and epigenetics is progressing
at an unprecedented pace and we anticipate more exciting
discoveries to arrive over the next few years. Yet technological
challenges are present that must be overcome to unravel
the mystery at the next level. As most metabolites are not diffus-
ible between mitochondria and cytosol/nucleus, accurate deter-
mination of the cytoplasmic pool size is critical to understand
their effects on epigenetic signaling. Although attempts have
been made, so far the technology to reliably measure metabolite
concentrations in different cellular compartments is lacking.
Even within the same compartment, local concentration of the
metabolite may vary, as substrate channeling is a common event
in cellular metabolism (Huang et al., 2001). This is relevant, as
metabolic enzymes are often present in transcriptional com-
plexes, and thus could provide a local supply of substrates/
cofactors to the complexes in which they localize. For example,
methionine adenosyltransferase IIa (MATIIa), which generates
SAM, was present in chromatin-associated complexes and
thought to provide local substrate for methyltransferases reac-
tions (Katoh et al., 2011). Alternatively metabolic enzymes may
function in these complexes independently of their metabolic
activity (Tristan et al., 2011; Yang et al., 2011). Finally, system
biology approaches will become increasingly important to fully
grasp the complexity of the connections between metabolism
and chromatin dynamics. A deeper understanding of these
connections may help shed light on our understanding of the
etiology of a variety of complex diseases (Katada et al., 2012;
Sahar and Sassone-Corsi, 2012).
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